# Edd Fleming

> Edd Fleming is a Series B investor at Enavate Sciences backing Health Care. See 6 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Enavate Sciences](https://shizune.co/investors/profile/enavate-sciences)
- Location: Palo Alto, United States
- Total investments: 6
- Last investment: Sep 2024
- Lead investor: 83%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/eddfleming

Edd Fleming is a Series B investor at Enavate Sciences in Palo Alto focused on Health Care and Medical. Edd Fleming is the Executive Vice President, Commercialization of Enavate Sciences. He previously worked at McKinsey & Company as a Senior Partner. Edd Fleming attended Harvard University.

## Contacts

5 contacts available for Edd Fleming: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/edd-fleming-96fd?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Medical | 2 | 33% |
| Biopharma | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Genetics | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 50% |
| Series A | 1 | 17% |
| Series C | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OrsoBio | OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $67M | Series B | Sep 06, 2024 | https://orsobio.com/ |
| Sionna Therapeutics | Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF). | $182M | Series C | Mar 06, 2024 | https://www.sionnatx.com/ |
| Sudo Biosciences | Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M | Series B | Feb 13, 2024 | https://www.sudobio.com |
| Sudo Biosciences | Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $116M | Series B | Dec 20, 2023 | https://www.sudobio.com |
| OrsoBio | OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $60M | Series A | Nov 07, 2023 | https://orsobio.com/ |
| Upstream Bio | Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses. | $200M | Series B | Jun 08, 2023 | https://www.upstreambio.com/ |

6 of 6 investments shown.

## Co-investors
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 3 deals together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 2 deals together
- [Eventide](https://shizune.co/investors/profile/eventide-asset-management) — VC Fund, 2 deals together
- [Frazier Life Sciences](https://shizune.co/investors/profile/frazier-life-sciences) — VC Fund, 2 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 2 deals together
- [Monograph Capital](https://shizune.co/investors/profile/monograph-capital) — VC Fund, 2 deals together

## About Enavate Sciences

VC Fund · Menlo Park, United States

Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies.

4 contacts available at Enavate Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christine Del Corsano | Chief Financial Officer | https://shizune.co/investors/profile/christine-del-corsano |
| Edd Fleming | Executive Vice President, Commercialization | https://shizune.co/investors/profile/edd-fleming-96fd |
| James Boylan | Chief Executive Officer | https://shizune.co/investors/profile/james-boylan |
| Robert Glassman | EVP, Search and Evaluation | https://shizune.co/investors/profile/robert-glassman-9763 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Edd Fleming invest in?

Edd Fleming invests primarily in Health Care, Medical and Biopharma startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Edd Fleming?

Public channels for Edd Fleming include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Edd Fleming last invest?

The most recent investment recorded for Edd Fleming closed in Sep 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co